Showing results (61-70 of 244) with videos related to

Sort By:
Pageof 25
Frontiers in Oncology|December 17, 2020
PELICAN-IPC 2015-016/Oncodistinct-003: A Prospective, Multicenter, Open-Label, Randomized, Non-Comparative, Phase II Study of Pembrolizumab in Combination With Neo Adjuvant EC-Paclitaxel Regimen in HER2-Negative Inflammatory Breast CancerAlexandre Bertucci, François Bertucci, Christophe Zemmour, et al.
International Journal of Breast Cancer|June 14, 2013
Time-Dependent Prognostic Impact of Circulating Tumor Cells Detection in Non-Metastatic Breast Cancer: 70-Month Analysis of the REMAGUS02 StudyFrançois-Clément Bidard, Lisa Belin, Suzette Delaloge, et al.
European Journal of Cancer (Oxford, England : 1990)|July 12, 2015
Cardiac toxicity events in the PHARE trial, an adjuvant trastuzumab randomised phase III studyXavier Pivot, Thomas Suter, Jean Marc Nabholtz, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 5, 2008
Circulating tumor cell detection predicts early metastatic relapse after neoadjuvant chemotherapy in large operable and locally advanced breast cancer in a phase II randomized trialJean-Yves Pierga, François-Clément Bidard, Claire Mathiot, et al.
Breast Cancer Research : BCR|February 15, 2012
Assessment of circulating tumor cells and serum markers for progression-free survival prediction in metastatic breast cancer: a prospective observational studyFrançois-Clément Bidard, David Hajage, Thomas Bachelot, et al.
Breast Cancer Research and Treatment|August 11, 2011
Final overall survival results and effect of prolonged (≥ 1 year) first-line bevacizumab-containing therapy for metastatic breast cancer in the ATHENA trialIan Smith, Jean-Yves Pierga, Laura Biganzoli, et al.
American Journal of Clinical Oncology|March 2, 2011
Pathologic response to short intensified taxane-free neoadjuvant chemotherapy in patients with highly proliferative operable breast cancerChristophe Le Tourneau, Sarah Dettwiler, Philippe Beuzeboc, et al.
European Journal of Cancer (Oxford, England : 1990)|July 30, 2005
Pharmacokinetic profile of cetuximab (Erbitux) alone and in combination with irinotecan in patients with advanced EGFR-positive adenocarcinomaCatherine Delbaldo, Jean-Yves Pierga, Véronique Dieras, et al.
Clinical & Experimental Metastasis|November 8, 2008
Time to metastatic relapse and breast cancer cells dissemination in bone marrow at metastatic relapseFrançois-Clément Bidard, Anne Vincent-Salomon, Brigitte Sigal-Zafrani, et al.
Bulletin Du Cancer|January 7, 2024
[The French National College of Oncology Teachers (CNEC): Missions, organization, and projects]Florence Huguet, Camille Tlemsani, Jean-Yves Pierga, et al.
Pageof 25